<DOC>
	<DOC>NCT01083888</DOC>
	<brief_summary>To assess the Pharmacokinetics and pharmacodynamics of single doses of ASP1517 in renal anemia patients on hemodialysis. Safety and tolerability will be also evaluated in these patients.</brief_summary>
	<brief_title>ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Chronic renal failure patients receiving hemodialysis thrice weekly Body weight: &gt;=40.0 and &lt;80.0 kg Mean hemoglobin level &gt;=10.0 and =&lt;12.0 g/dL Patients with severe inflammation or infection Patients who have a medical history of gastrointestinal surgery or enterectomy Patients who have uncontrolled hypertension Patients whose AST, ALT, total bilirubin, GGT exceed the ULN or those who have a medical history of serious liver diseases Patients who have a medical history of severe cardiac or cerebrovascular diseases Patients who have received blood transfusion or who have had a surgery (except surgery for a shunt) within 4 weeks Patients with a medical history of serious drug allergies Patients who may be pregnant or lactating, or who refuse to use required birth control during the study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety and tolerability</keyword>
	<keyword>Plasma concentration</keyword>
	<keyword>ASP1517</keyword>
	<keyword>FG-4592</keyword>
</DOC>